Replimune Group, Inc. (NASDAQ:REPL) COO Colin Love sold 15,000 shares of Replimune Group stock in a transaction dated Monday, November 16th. The shares were sold at an average price of $44.91, for a total value of $673,650.00. Following the completion of the sale, the chief operating officer now directly owns 1,021,224 shares in the company, valued at approximately $45,863,169.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Replimune Group stock opened at $49.99 on Friday. Replimune Group, Inc. has a 52 week low of $8.58 and a 52 week high of $54.85. The company has a debt-to-equity ratio of 0.12, a quick ratio of 22.54 and a current ratio of 22.54. The stock has a market capitalization of $2.30 billion, a P/E ratio of -30.11 and a beta of 3.23. The stock has a 50-day simple moving average of $39.05 and a 200 day simple moving average of $26.24.
Replimune Group (NASDAQ:REPL) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.03). Research analysts forecast that Replimune Group, Inc. will post -1.78 earnings per share for the current year.
A number of analysts recently issued reports on REPL shares. BidaskClub raised Replimune Group from a “hold” rating to a “buy” rating in a research report on Thursday, October 22nd. BMO Capital Markets lifted their target price on Replimune Group from $51.00 to $57.00 and gave the company an “outperform” rating in a research report on Friday, November 6th. Jefferies Financial Group started coverage on Replimune Group in a research report on Monday, November 2nd. They issued a “buy” rating and a $67.00 target price on the stock. BTIG Research started coverage on Replimune Group in a research report on Tuesday, November 17th. They issued a “buy” rating and a $60.00 target price on the stock. Finally, Chardan Capital lifted their target price on Replimune Group from $30.00 to $48.00 and gave the company a “buy” rating in a research report on Wednesday, October 14th. Two analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $51.22.
Replimune Group Company Profile
Replimune Group, Inc, a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma.
Further Reading: What are no-load funds?
Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.